Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Nature Medicine|July 10, 2025
A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trialChang Liu, Dan Liu, Yinghua Ji, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I studyQing Zhou, Nong Yang, Mingfang Zhao, et al.
The Lancet. Respiratory Medicine|July 26, 2024
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 studyJin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, et al.
Journal of Hematology & Oncology|November 12, 2024
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trialFeng Bi, Jian Dong, Chuan Jin, et al.
Experimental Hematology & Oncology|November 22, 2025
Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumorsRongrui Liu, Rongbo Lin, Ning Li, et al.
The New England Journal of Medicine|May 29, 2026
First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion MutationsCaicun Zhou, Laurent Greillier, Geoffrey Liu, et al.
Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
Translational Lung Cancer Research|May 19, 2025
Efficacy and safety of finotonlimab plus docetaxel <i>vs.</i> docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trialBaohui Han, Lin Wu, Runxiang Yang, et al.
Nature Communications|January 16, 2026
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trialChuntao Gao, Yanqiao Zhang, Xiujuan Qu, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2025
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trialChunmei Bai, Yi Zheng, Meili Sun, et al.
Pageof 12